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Abstract
The study of Parkinson’s disease (PD), like other complex neurodegenerative disorders, is limited by access to brain tissue
from patients with a confirmed diagnosis. Alternatively the study of peripheral tissues may offer some insight into the
molecular basis of disease susceptibility and progression, but this approach still relies on brain tissue to benchmark relevant
molecular changes against. Several studies have reported whole-genome expression profiling in post-mortem brain but
reported concordance between these analyses is lacking. Here we apply a standardised pathway analysis to seven
independent case-control studies, and demonstrate increased concordance between data sets. Moreover data convergence
increased when the analysis was limited to the five substantia nigra (SN) data sets; this highlighted the down regulation of
dopamine receptor signaling and insulin-like growth factor 1 (IGF1) signaling pathways. We also show that case-control
comparisons of affected post mortem brain tissue are more likely to reflect terminal cytoarchitectural differences rather than
primary pathogenic mechanisms. The implementation of a correction factor for dopaminergic neuronal loss predictably
resulted in the loss of significance of the dopamine signaling pathway while axon guidance pathways increased in
significance. Interestingly the IGF1 signaling pathway was also over-represented when data from non-SN areas, unaffected
or only terminally affected in PD, were considered. Our findings suggest that there is greater concordance in PD whole-
genome expression profiling when standardised pathway membership rather than ranked gene list is used for comparison.
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Introduction
Parkinson’s disease (PD, OMIM: #168600) is a uniquely
human disease that is clinically characterised by cardinal motor
symptoms such as postural instability, bradykinesia and resting
tremor [1]. In the PD brain there is pathognomonic loss of more
than 50% of the dopaminergic neurons in the substantia nigra pars
compacta (SNc) located in the midbrain [2,3]. However, the
disease is also characterised by non-motor symptoms such as sleep
disorders, depression, hyposmia and autonomic dysfunction [4–7].
Accordingly, pathology in PD is not just restricted to the SNc but
also affects the olfactory pathway, spinal cord and dorsal cranial
nuclei of the medulla [8–11].
High throughput discovery platforms, such as microarrays, that
assume no a priori aetiological hypotheses, promise much in
elucidating the pathogenesis of complex diseases such as PD.
Moreover, one would hope that these microarray data would
reveal clues previously inaccessible via other means. Several
microarray-based studies have used human tissue to look for
differentially expressed genes in Parkinson’s disease [12–21]. The
majority of these used post-mortem whole brain tissue from the
substantia nigra (SN) [14–17] and although most authors
emphasised differential expression in the ubiquitin-proteasome
system or cellular energy pathways, their published gene lists
appeared quite discordant. Others extended their studies to
include pathologically normal brain regions [12,18,20,21] and
these highlighted other biological mechanisms such as G-Protein-
coupled receptor signaling and transcriptional regulation.
One study assayed SNc dopaminergic neurons only, following
isolation by laser capture microscopy (LCM) [13]. Here gender
differences were more pronounced than PD versus control
differences. Uniquely, one study compared the transcriptomes of
whole blood samples [19] and reported expression differences in a
number of unrelated genes.
Given an apparent lack of concordance in published data sets
one might ask what relevance these transcriptional approaches can
have to PD pathogenesis. Certainly the utilisation of post mortem
brain tissue appears to represent the best opportunity for finding
PD-specific changes in gene expression. Furthermore such
‘benchmarks’ facilitate the evaluation of clinical samples and
model systems for their utility in PD research. However the
approaches to generating and analysing microarray data are not
standardised and therefore could account for much of the
apparent discrepancy between reported gene lists.
PLoS ONE | www.plosone.org 1 March 2009 | Volume 4 | Issue 3 | e4955Here we apply a common analytical approach to the available
human transcriptomic data in an attempt to find greater data
convergence and generate new insight into the pathways
systematically altered during PD pathogenesis. We have also
generated an online search tool and extend an invitation to other
researchers to explore the data themselves http://ncascr.griffith.
edu.au/pdreview/2008/.
Results
Demographics of microarray studies using PD case-
control tissue
Ten published transcriptomic studies met the initial criterion of
comparing primary tissues derived from PD patients and controls
(Table 1). Of these, seven were included because they used the
same common gene expression array. These seven studies
provided 13 case-control data sets comparing tissue from 119
PD cases and 74 controls (Table 2). Three studies did not meet the
inclusion criteria: (1) Grunblatt et al. [15] who used a Focus array
(Affymetrix) with limited gene coverage; (2) Miller et al [22] who
used the Codelink
TM bioarray platform and (3) Bossers et al. [12]
who used Agilent technology. We were also unable to source raw
data from the study of Papapetropoulos and colleagues [18].
Although the raw data from these latter experiments was not
included in our combined re-analysis, their published gene lists
were used when initially evaluating data convergence between all
studies.
Lack of convergence of pathways between studies from
published ranked gene lists
We postulated, as others had done previously, that genes and
pathways that appear consistently as differentially expressed in
multiple studies and different source tissues are likely to be
important in PD [20]. To look for such convergence we compared
the published lists of differentially expressed genes using the
Ingenuity Pathways Analysis (IPA) package. There was little
overlap between published ranked gene lists and there were no
genes consistently identified in more than three datasets (Table S1
). We then asked whether we would see greater convergence using
pathway analysis of the originally reported ranked gene lists. The
ERK/MAPK was the most highly represented pathway, although
it was over-represented in only four of the 11 data sets (Table 3).
Application of common data analysis methodology
Our common analysis method was applied to the 13 datasets
(from seven studies) that met our platform inclusion criteria, and
new ranked probe lists were produced. These are listed in Table
S2, while the number of differentially-expressed probes is shown in
Table 2. Additionally these data can be viewed online http://
ncascr.griffith.edu.au/pdreview/2008/. This improved the con-
vergence of the genes between the datasets with 20 genes now
consistently differently regulated across six of 13 datasets (data not
shown). Ranked IPA pathways from these gene lists can be found
in Table S3.
Pathway analysis of SN data sets reveals a common
dysregulation of dopamine signaling
Dopaminergic neuron loss in the SNc is the prominent
neuropathological entity in PD so we initially focused on the SN
data sets for their convergence and reproducibility. Over-
representation of the dopamine receptor signaling pathway was
consistently and significantly observed in all SN data sets (p-values
.0.003–0.026) suggesting that not only can PD-related pathways
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PLoS ONE | www.plosone.org 2 March 2009 | Volume 4 | Issue 3 | e4955be dissected out of complex transcriptomic data but that these
changes are robustly reproducible between comparable studies
(Table 4 and Table S2 A–E for full ranked pathway lists).
Neuronal loss in PD is more severe in the lateral SN compared
to the medial SN [23–25] while areas such as the superior frontal
gyrus (SFG) are largely unaffected. A comparison of these three
anatomical areas from the data in Moran et al. (LSN v MSN v
SFG) showed a direct correlation between fold changes in genes of
dopamine receptor signaling pathway and the severity of PD
neuronal loss [14]. Therefore, the prominence of this pathway
appeared to represent the disparate numbers of residual
dopaminergic neurons in PD compared to control brains.
Correcting for dopaminergic neuronal loss changes
ranked pathways
In order to bias our analysis towards underlying pathogenic
mechanisms rather than terminal pathology, we devised a
correction paradigm based on Moran’s observations on neuronal
loss. Our rationale is described in detail in Table S4. 217 genes with
foldchangesLSN.MSN.SFGfrom the Moranetal.data setswere
defined as potentially ‘‘neuronal-loss-associated’’, as these were the
genes whose differential expression most likely resulted from relative
loss of dopaminergic neurons from the brain regions sampled,
rather than transcriptomic differences in residual cells. However
eight of these genes could be shown to be differentially expressed in
residual dopaminergic neurons (Cantuti-Castelvetri et al. study)[13]
and so were retained in the analysis. The removal of 209 genes
(Table S5) from the SN ranked lists resulted in two alternative
pathways gaining prominence: ephrin receptor signaling (p-values
,0.003–0.04) and the axonal guidance pathway (p-values ,0.004–
0.049) (Table 4 and Table S6 A–E for full ranked pathway lists).
Assessment of glial contribution to the neuronal-loss
corrected datasets
Given the loss of dopaminergic cells in the PD SN the major
contribution to the expression profile in the SN PD samples would
presumably now come from the non-dopaminergic cells. Further-
more neuropathology in the PD SN is characterised by a reactive
gliosis or ‘‘glial inflammation’’ (reviewed by Orr et al., 2002) [26].
Therefore glial markers and in particular reactive microglia
markers such as CD68 and ICAM-1 might be expected to be
upregulated in the SN data sets [26,27]. However these genes and
those of glial markers in general were largely indifferent between
PD and controls. This potential anomaly is illustrated further using
a selection of PD-related glial markers (Table S7).
Analysis of non-SN brain tissue highlights growth factor
signaling pathways
We also analysed non-SN tissues as they are not subject to
cytoarchitectural changes seen in the SN or are only affected late in
the disease. Five IPA pathways were overrepresented in three out of
Table 2. Summary of each data set used in the re-analysis and the number of differentially expressed probes before and after
neuronal correction.
Studies
Number of PD patients
used in microarray
analysis
Number of controls used
in microarray analysis
RNA tissue
source
Number of differentially
expressed probes #0.01
Number of differentially
expressed probes #0.01
after neuronal correction
*
Substantia nigra Data Sets
Hauser 6 5 SN 159 152
Zhang 11 18 SN 1014 951
Moran 15 6 LSN 1975 1779
Moran 15 6 MSN 2149 1924
Lesnick 16 9 SN 2030 1993
Other Non-SN Brain Regions Data Sets
Zhang 14 19 BA9 2373 -
Zhang 15 15 PT 197 -
Moran 15 6 SFG 598 -
Vogt 4 4 OCTX 1727 -
Vogt 3 3 PT 155 -
Vogt 4 4 CB 174 -
Other Data Sets
Castelvetri 8 8 LCM DA-SN 491 -
Scherzer 55 22 Blood 208 -
*no probes were removed from the non-SN brain regions data sets.
doi:10.1371/journal.pone.0004955.t002
Table 3. Summary of over-represented IPA pathways from
the published array data.
IPA Pathway category
Number of studies with over-
represented pathways at #0.05 in all
published lists (11)
ERK/MAPK Signaling 4
G-Protein Coupled Receptor
Signaling
3
Huntington’s Disease Signaling 3
a-Adrenergic Signaling 3
Synaptic Long Term Potentiation 3
PPARa/RXRa Activation 3
doi:10.1371/journal.pone.0004955.t003
Analysis of Parkinsons Disease
PLoS ONE | www.plosone.org 3 March 2009 | Volume 4 | Issue 3 | e4955five non-SNdata sets(Table5).Ofthese,IGF-1andVEGFsignaling
were also found to be dysregulated in two of the neuronal loss-
corrected SNdatasets.Whereas,thefourpathways(PTEN signaling,
JAK/STAT signaling, ephrin receptor signaling, axonal guidance
signaling) found to be significance in three or more of the corrected
SN datasets were only significance in two of the non-SN datasets.
Differential expression in whole blood
Finally, given its clinical accessibility, we also re-analysed a
whole blood dataset [19]. Our analysis revealed that the inositol
phosphate metabolism and VEGF signaling pathways were the
most differentially expressed in this dataset. The prominence of
these pathways was quite distinct from SN tissues but commonality
with non-SN tissues was observed with the VEGF signaling
pathway (Table S2 L).
Discussion
Microarrays promise much in elucidating the pathogenesis of
complex diseases such as PD but the lack of concordance in
published data sets to date certainly questions their relevance.
Here we have shown that a standardised approach to analysing
PD-related microarray data can account for a considerable
proportion of the discordance. We used a common analytical
approach which improved data convergence and uncovered new
leads for PD pathogenesis. We also recognised a potential
anatomical bias in the datasets derived from brain regions with
high neuronal loss. Our approach therefore provided an improved
comparative analysis between existing datasets and further
considered ‘tissue-of-origin’ effects.
Pathway analysis may uncover concordance between
datasets not found in gene lists
Complex phenotypes, by their very nature, are aetiologically
heterogeneous. This implies that single gene signatures may not be
shared by all affected individuals. However, the identification of
particularly relevant genetic pathways, have a higher probability of
being revealed as convergent across multiple individuals and
multiple studies than individual genes per se. Moreover, the
differences reflected in a pathway or network of genes may be
robust enough to overcome the effects of experimental noise and
inter-study variability prone to bias single gene expression values.
Therefore, this approach results in an increase in sensitivity to
detect interesting and novel patterns in gene expression between
multiple samples of cases and controls.
Common data analysis highlights dopamine signaling
pathway in SN
Context is very important in gene expression studies and as
expected the analysis of SN tissue-derived data sets further
improved our concordance and highlighted the ‘dopamine
receptor signaling’ pathway. However rather than representing a
primary pathogenic effect the extensive down regulation of genes
such as DOPA decarboxylase (DDC), dopamine receptor 2
(DRD2), dopamine transporter (SLC6A3 or DAT) and tyrosine
hydroxylase (TH) was probably entirely due to a disproportionate
number of SN dopaminergic neurons between cases and controls.
On a positive note, the microarray data was providing accurate
molecular fingerprints of the comparative tissue being examined; a
Table 4. Summary of over-represented IPA pathways in the
SN data sets before and after neuronal correction.
IPA Pathway category
Number of
studies with
over-represented
pathways at
#0.05 in SN
data sets (n=5)
Number of
studies with
over-represented
pathways at
#0.05 in SN data
sets (n=5) after
neuronal correction
Dopamine Receptor
Signaling
51
IGF-1 Signaling 3 2
PTEN Signaling 3 3
JAK/Stat Signaling 3 3
Glucocorticoid Receptor
Signaling
33
Huntington’s Disease
Signaling
33
PPAR Signaling 3 3
Ephrin Receptor Signaling 2 4
VEGF Signaling 2 2
Axonal Guidance Signaling 2 3
PI3K/AKT Signaling 2 2
Insulin Receptor Signaling 2 2
BMP signaling pathway 2 2
Synaptic Long Term
Depression
22
Synaptic Long Term
Potentiation
20
PDGF Signaling 2 1
B Cell Receptor Signaling 2 2
Lysine Degradation 2 2
Estrogen Receptor Signaling 2 2
G-Protein Coupled Receptor
Signaling
20
Inositol Phosphate
Metabolism
21
IL-2 Signaling 2 1
doi:10.1371/journal.pone.0004955.t004
Table 5. Comparison of over-represented IPA pathways in
non-SN data sets and neuronal-loss corrected SN data sets.
IPA Pathway category
Number of
studies with
over-represented
pathways at
#0.05 in non-SN
data sets (n=6)
Number of
studies with
over-represented
pathways at #0.05
in SN data sets
(n=5) after
neuronal correction
IGF-1 Signaling 3 2
VEGF Signaling 3 2
Synaptic Long Term
Potentiation
30
Calcium Signaling 3 0
ERK/MAPK Signaling 3 0
PTEN Signaling 2 3
JAK/Stat Signaling 2 3
Ephrin Receptor Signaling 2 4
Axonal Guidance Signaling 2 3
doi:10.1371/journal.pone.0004955.t005
Analysis of Parkinsons Disease
PLoS ONE | www.plosone.org 4 March 2009 | Volume 4 | Issue 3 | e4955modern pixelated analogy to the histological section. However the
relative neuronal loss in the SN also reduced our signal to noise
ratio for pathogenic relevance.
Accordingly we pursued two alternative approaches to maxi-
mise potentially useful information on the underlying biological
processes. First, the implementation of a correction factor for
dopaminergic neuronal loss in the SN data sets and second, the
analysis of non-SN or unaffected tissues for data convergence. The
purpose of the correction factor was not to magically recreate the
early disease landscape but to remove ‘red herrings’ that solely
reflected the relative numbers of neurons between cases and
controls. The retention of genes differentially regulated in the
residual dopaminergic neuron data set should have improved the
overall specificity of this approach.
Following our ‘neuronal loss’ correction, two alternative
pathways gained prominence: ephrin receptor signaling and the
axonal guidance pathway. The latter is consistent with the findings
of recent studies [12,28] including one that combined gene
expression data with genotype data from two genome-wide
association studies [28]. There is actually considerable overlap
between the axon guidance and ephrin signaling pathways with
ephrins along with netrins, slits and semaphorins being the main
families of guidance molecules in the developing nervous system
[29]. It remains to be clarified whether the differential expression
of axon guidance genes in PD represent neurodevelopmental
manifestations, compensatory attempts at rewiring, or dysregulat-
ed expression patterns induced by a devastated environment.
As discussed above microarray data is very powerful in
illustrating cytoarchitectural differences between cases and con-
trols such as dopaminergic neuron loss. Given the considerable
literature supporting the involvement of glia in PD pathogenesis
[26,27,30,31] we might have expected glial markers to inversely
differentiated in the SN data sets. The absence of significant fold
changes in activated microglial markers in particular argues
against a substantial glial component to neurodegeneration in the
terminal PD brain.
Growth factor signaling pathways are prominent in non-
SN tissues
The distinct gene expression pattern of brain areas that are not
overtly affected by PD pathology may be less confounded than the
SN with respect to the cell death associated with PD. It could be
argued that the transcriptomes of unaffected tissues might be too
divergent from those of predilection sites such as the SN, such that
they provide very little informative data. Our analysis, which has
highlighted consistent differences in growth-factor signaling in
non-SN datasets, argues that areas affected late in the disease, such
as the prefrontal cortex [8] could at the time of post mortem
exhibit similar mechanisms of degeneration as initially occurred in
the SN. Our approach highlights the differential expression of
IGF-1 and VEGF signaling pathways. Importantly the IGF1
signaling pathway was also over-represented in two ‘corrected’ SN
datasets (Table 5).
This pathway has been largely unexamined for associations with
PD although IGF1 signaling is reported to have neuroprotective
effects on dopaminergic neurons [32,33] and it has recently been
suggested that excessive IGF1 signaling accelerates ageing through
deleteriously effects on protective mechanisms against proteotoxi-
city such as Lewy body formation in PD [34]. Furthermore we
have recently showed that a polymorphism in the 39 untranslated
region of the IGF2 gene, a homologue of IGF1 was protective
against PD [35].
Similarly VEGF is known to promote the growth and survival of
dopaminergic neurons [36–38] Interestingly both IGF1 and
insulin enhance VEGF expression in vitro [39,40] providing a
plausible mechanism that might underlie the co-prominence of
these signaling pathways in our re-analysis.
Challenges and Future Directions
Case-controlexpression analysis ina degenerative disease likePD
poses difficult issues when attempting to uncover pathways
contributing to disease initiation. It would be advantageous to
target tissues that express the proteins that are fundamental to the
disease process and are different in individuals who are at risk of the
disease. At the same time we need to account for any influences of
the pathological process on these profiles. Microarray data of
predilection sites such as the SN illustrates cytoarchitectural
differences between cases and controls but to understand some of
the early pathogenic processes, we would ideally want to assay a
brain region very similar to SN but that is only belatedly affected.
An additional consideration is the ability of the pathway
approach, used in our analyses, to provide adequate specificity for
PD over other neurodegenerative conditions. This issue remains to
be clarified, and requires further investigation. It is important to
recognise that there may be genetic expression patterns common
to neurodegenerative diseases, generally. These may reflect
common pathological changes (such as cell death, markers of
oxidative stress or neuro-inflammation etc) or shared risk factors
influencing neurodegeneration.
There are still inherent difficulties in obtaining reproducible
gene expression data from post mortem brain, even if an optimal
region of the brain could be assayed [41–44]. Furthermore this
information can only be used retrospectively for the potential
benefit of future PD patients. Therefore there is considerable
interest in developing strategies to obtain human RNA from more
accessible sources such as blood or neuronal-like cell lines. The
finding of down regulation of a-synuclein in microarray analysis of
whole blood samples from PD patients versus controls is exciting
because it implies that PD-specific changes can be found ante
mortem in readily accessible tissues [19]. It is also of note that these
tissues also revealed differential expression of the VEGF signaling
pathway (observed in other non-SN tissue samples). However,
there is a real risk that peripheral tissues, such as whole blood
examined here, may express few proteins fundamental to the
disease process and therefore be of limited ability to demonstrate
case - control differences relevant to nervous system disorders [45].
The lack of available gene expression data from multiple tissues in
PD patients at various stages of the disease prevents such an
analysis but highlights the need for ongoing research efforts in this
area.
Interestingly one peripherally accessible neural tissue, the
olfactory mucosa, has been used to demonstrate significant
differences in functional assays and gene expression between
schizophrenics, bipolar affective disorder and controls [46]. Such
cells from PD patients and controls may yet provide an
opportunity to interrogate neuronal mechanisms without relying
on post mortem tissue [47].
In this paper we have presented a summary of the available
microarray data from PD case-control studies and have suggested
some potential strategies for uncovering primary pathogenic
mechanisms. For others who wish to use and explore these data
we have constructed an online database which enables rapid
evaluation on a single gene or pathway basis.
Materials and Methods
We conducted literature searches in National Center for
Biotechnology Information (NCBI) PubMed and dataset searches
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to identify all reported microarray studies that explored differential
gene expression in Parkinson disease. Studies satisfied the inclusion
criteria if they: 1) compared tissues from PD patients and controls;
2) assessed transcripts on a genome-wide basis; and 3) used
Affymetrix gene expression arrays. For the selected studies we
obtained raw microarray data (CEL files) from public microarrays
repositories [13,14,19] or from the study authors [16, Vogt, 2006
#1529,21,]. In one case the data was publicly available from the
follow up study [28] rather than the primary study [18].
Meta-analysis data summarisation, normalisation and
analysis of variance
All studies used Affymetrix arrays, the probes on the arrays and
the experimentally chosen fluorescence thresholds varied. Conse-
quently, the data could not be simply combined without avoiding
study bias and the effects of probe-level sequence information [50].
To overcome this problem, the raw data (as CEL files) for each
dataset were imported individually into GeneSpringH
TM
7.3.1(Agilent) and the probes sets were summarised and normal-
ised by the Robust Multichip Average (RMA) algorithm[51].
Some studies included non-PD disease controls but our analysis
was performed on PD and control patients only (Table 1). For
studies which used multiple brain regions, each area was treated as
a separate data set. Differentially expressed genes between PD and
controls were determined by an analysis of variances (ANOVA)
using a Welch t-test with a p-value cut-off of #0.01.
Pathway over-representation analysis
The ranked genes lists for each study were assessed by integrating
the data at a pathway level. Each ranked list was imported into the
Ingenuity Pathways Analysis 6.3 (IPA, from IngenuityH Systems,
www.ingenuity.com) which incorporates an extensive literature-
derived knowledge base from which to assign pathway affiliation.
The significance value for pathway over-representation was
calculated using a right-tailed Fisher’s exact test. Each pathway
was ranked by assessing the number of studies that were statistically
over-represented (p-value #0.05). This pathway over-representa-
tion ranking was performed individually on data sets utilising
substantia nigra (SN) (Hauser, Moran LSN+MSN, Zhang,
Lesnick)[14,16,21,28] and non-SN tissues (Zhang-Putamen,
Zhang-BA9, Moran-SFG, Vogt-OCT, Vogt-Putamen, Vogt-
CB)[14,20,21]. Additionally this analysis was performed indepen-
dently on data sets derived from whole blood (Scherzer)[19] and
dopaminergic neurons (Cantuti-Castelvetri)[13].
Correction for dopaminergic neuronal loss
The substantia nigra pars compacta of PD patients is
characterised by the loss of neuromelanin-containing dopaminer-
gic neurons [2,3]. Furthermore neurons are lost in a particular
pattern; severity decreasing from ventrolateral to dorsomedial [23–
25]. In an attempt to correct for the effects on expression arising
directly from the neuronal loss associated with PD, we devised the
following correction paradigm. We first used data from the Moran
et al. study[14] which compared gene expression profiles in three
brain regions, lateral SN (LSN), medial SN (MSN) and superior
frontal gyrus (SFG), from the same patients. The actual neuronal
loss in PD is known to be greater in LSN compared to MSN, with
the SFG relatively spared. Therefore significant probes (p#0.01)
with fold changes in LSN.MSN.SFG were defined as
potentially ‘‘neuronal-loss-associated’’. For example the tyrosine
hydroxylase (TH) gene showed a fold change pattern of 214.5
(LSN), 24.9 (MSN) and no change (SFG). Any probes which were
defined as ‘‘neuronal-loss-associated’’ and were not differentially
expressed in residual laser-captured dopaminergic neurons
(Cantuti-Castelvetri et al. study)[13] were removed from the
subsequent analyses of all SN data sets.
Online Database
The differentially expressed gene list generated for each study
by this re-analysis can be found with their respective p-values and
fold changes can be found at http://ncascr.griffith.edu.au/pdre-
view/2008/. A search can be performed individually using Entrez
gene ID, gene symbol, or collectively by publicly available lists/
pathways.
Accession Numbers
The National Center for Biotechnology Information Entrez
Gene website (http://www.ncbi.nlm.nih.gov/sites/entrez?db=-
gene) accession numbers (GeneIDs) for the genes named in the
paper include: DDC(1644), DRD2(1813), SLC6A3(6531), TH(7054),
IGF2(3481).
Supporting Information
Table S1 Comparison of overlap in genes between PD-related
transcriptomic studies. The enclosed table illustrates the increase
in data convergence between PD-related transcriptomic studies
following the implementation of our common analysis methodol-
ogy.
Found at: doi:10.1371/journal.pone.0004955.s001 (0.02 MB
PDF)
Table S2 The differentially expressed probes generated by
common analysis for each study. Ranked probe lists for each study
generated by common analysis method with fold change and p-
value.
Found at: doi:10.1371/journal.pone.0004955.s002 (1.08 MB
XLS)
Table S3 Over-represented pathway categories from IPA
analysis. Over-represented pathway categories from IPA analysis
of the differentally expressed probes of PD patients compared to
controls: A- SN - Hauser study; B- SN - Zhang study; C- lateral
SN - Moran study; D- medial SN - Moran study; E- SN - Lesnick
study; F- Brodmann Area 9 - Zhang study; G- Putamen - Zhang
study; H- Superior Frontal Gyrus - Moran study; I- Occipital
Cortex - Vogt study; J- Putamen - Vogt study; K- Cerebellum -
Vogt study; L- Whole Blood - Scherzer study; M- Laser Captured
SN dopaminergic neurons - Castelvetri study.
Found at: doi:10.1371/journal.pone.0004955.s003 (0.07 MB
XLS)
Table S4 Selection of neuronal loss-associated genes. A work
flow diagram and hypothetical examples illustrate the selection of
neuronal loss-associated genes that were removed from the SN
datasets prior to pathway analysis.
Found at: doi:10.1371/journal.pone.0004955.s004 (0.12 MB
PDF)
Table S5 ‘Neuronal-loss’ associated genes removed by correc-
tion paradigm. Identified probes with fold change’s for the three
brain regions in the Moran study that followed the pattern,
LSN.MSN.SFG.
Found at: doi:10.1371/journal.pone.0004955.s005 (0.05 MB
XLS)
Table S6 Identified probes with fold change’s for the three brain
regions in the Moran study that followed the pattern,
LSN.MSN.SFG. Over-represented pathway categories from
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expressed probes from SN tissue: A- Hauser study; B- Zhang
study; C- lateral SN; Moran study; D- medial SN Moran study; E-
Lesnick study.
Found at: doi:10.1371/journal.pone.0004955.s006 (0.04 MB
XLS)
Table S7 Fold changes in PD-related glial markers. The lack of
differential expression of PD-related glial markers is illustrated in
the enclosed table.
Found at: doi:10.1371/journal.pone.0004955.s007 (0.07 MB
PDF)
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